The news roiled pharmaceutical stocks, while Amazon shares are at all-time highs.
According to Tanquilut, Amazon’s business-to-business medical device web page was posted during the same period the company was granted wholesale distribution licenses in several states. The licensure was first reported by the St. Louis Post-Dispatch.
An Amazon spokesperson previously told CNBC by email of which the company doesn’t “comment on rumors or speculation.”
While many have speculated these licenses could be used for drugs, Tanquilut said the timing could indicate Amazon can be more interested in medical devices.
“[T]he out-of-state wholesaler license of which AMZN filed with the state of Nevada revealed of which AMZN did not select ‘Controlled Substances’ as a type of product of which they might be handling,” Tanquilut wrote in a Friday research note.”While we acknowledge of which there are prescription drugs of which don’t fall under the definition of ‘controlled substances’, the active decision to choose not to distribute those types of drugs leads us to believe of which AMZN will not be using these licenses to distribute any prescription drugs[.]”
On the additional hand, Wells Fargo analyst David Maris pointed out of which AmazonRX.com redirects to the Amazon home page.
“We find the idea easy to envision of which, if the idea entered pharmacy, Amazon could offer unique value to some customers, such as the easier ability to manage prescriptions along with perhaps discounts, such as free generics to Prime users,” Maris wrote. Overall, we think of which even though Amazon has not stated a goal to be in pharmacy, history has shown the idea can be better to consider Amazon’s disruptive potential beforehand rather than afterward.”
— CNBC’s Christina Farr, Dan Mangan, Evelyn Cheng along with Thomas Franck contributed to This kind of report.